The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study.
 
Marijo Bilusic
Research Funding - Bavarian Nordic (Inst); ImmunityBio (Inst); Merck (Inst); NextCure (Inst); Surface Oncology (Inst)
 
NIcole J Toney
No Relationships to Disclose
 
Renee Nicole Donahue
No Relationships to Disclose
 
Fatima Karzai
No Relationships to Disclose
 
Ravi Amrit Madan
Speakers' Bureau - Boehringer Ingelheim (I); Janssen (I); Pfizer (I)
Research Funding - Bayer
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst); EMD Serono/Merck (Inst); ImmunityBio (Inst); Incyte (Inst); NextCure (Inst); PDS Biotechnology (Inst); Precigen (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Priyamvada Rai
No Relationships to Disclose
 
Cassie Due
No Relationships to Disclose
 
Philip Gregory
No Relationships to Disclose
 
Beatriz Mateo-Victoriano
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb/Medarex; Calithera Biosciences; EMD Serono; Exelixis; IMV; Janssen; Janssen; MEI Pharma; Merck; Pfizer; Regeneron; Seattle Genetics/Astellas; Signatera
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)